Clinical trials
Prostate Cancer Patients Treated by Radiotherapy clinical trials
Below are recruiting prostate cancer patients treated by radiotherapy clinical trials, each written for real people, not researchers. We’re tracking 269 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05893381RecruitingPhase 2
Targeted PSMA scan plus focused radiation vs radiation alone
This trial tests whether adding a PSMA-targeted radioactive medicine (Lu-PSMA) to focused stereotactic radiation to a few prostate cancer spots works better than radiation alone. It may help people with limited, asymptomatic spread of prostate cancer by improving cancer control while carefully monitoring side effects.
Cesena, FCAges 18 years+ - NCT05805371RecruitingPhase 1
PSCA CAR-T cells with or without radiation for prostate cancer
This Phase 1 study tests a prostate cancer treatment made of PSCA-targeted CAR-T cells, with or without radiation, to help control advanced prostate cancer. It aims to find a safe treatment approach and see how well it works in people whose cancer has PSCA.
Duarte, CaliforniaAges 18 years+ - NCT05766371RecruitingPhase 2
Immunotherapy plus targeted radiation for advanced prostate cancer
This study combines two treatments: pembrolizumab, which helps your immune system fight cancer, and a targeted radioactive medicine (177Lu-PSMA-617) that seeks out and damages prostate cancer cells. It may help men whose prostate cancer has spread despite initial hormone therapy.
San Francisco, CaliforniaAges 18 years+ - NCT05616650RecruitingPhase 2
Targeted radiation for one prostate tumor spot
This Phase 2 study tests a focused radiation approach using stereotactic body radiation therapy (SBRT) for people with one prostate tumor visible on imaging. It aims to treat a single tumor area while limiting treatment to the rest of the prostate.
Bethesda, MarylandAges 18–120 - NCT05183074Recruiting
MRI-guided focused radiation for prostate cancer
This trial tests a newer way to plan and deliver radiation for prostate cancer using real-time MRI guidance. It may help by aiming high-dose treatment precisely while treating nearby disease and (in some cases) limited metastatic spots.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05521412RecruitingPhase 1/Phase 2
PSMA-targeted radioligand for advanced prostate cancer
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
Melbourne, VictoriaAges 18 years+ - NCT05489211RecruitingPhase 2
Testing a cancer drug for advanced solid tumors
This Phase 2 study tests the drug Dato-DXd (alone or with other cancer medicines) in people with advanced solid tumors. It looks for tumor shrinkage and how safely the treatment can be given.
Los Angeles, CaliforniaAges 18–130 - NCT05346848RecruitingPhase 2
Darolutamide plus radiation for intermediate-risk prostate cancer
This trial tests whether adding darolutamide to standard radiation can better control intermediate-risk prostate cancer. It includes men whose cancer has spread nowhere else and who are newly diagnosed with “unfavorable intermediate risk” or progress to that risk group.
AvignonAges 18 years+ - NCT04983095Recruiting
Targeted radiation for a few prostate cancer metastases
This trial looks at whether a precise form of radiation (stereotactic body radiotherapy) can control a small number of prostate cancer spots seen on a special scan (PSMA PET/CT). It may help by treating limited metastases while avoiding unnecessary treatment elsewhere.
Lund, LundAges 18 years+ - NCT04947254RecruitingPhase 2
Add niraparib to hormone therapy after prostate radiation
This Phase 2 trial tests whether adding niraparib to standard hormone therapy (androgen ablation) after radiation works better for men with high-risk, localized or locally advanced prostate cancer. It may help control the cancer for longer, while also collecting extra tissue and blood to study why the treatment works or doesn’t.
Houston, TexasAges 18 years+ - NCT04946370RecruitingPhase 1/Phase 2
Pembrolizumab plus prostate cancer drug, with or without radiation
This early-phase trial tests pembrolizumab (an immune therapy) plus an androgen-receptor–blocking prostate cancer drug, and possibly a targeted radiation treatment. It’s for men with prostate cancer that has spread and keeps worsening despite standard hormone therapy, aiming to shrink tumors and improve control of the disease.
Boston, MassachusettsAges 18 years+ - NCT04787744RecruitingPhase 2/Phase 3
Test standard prostate cancer treatment with or without targeted spot radiation
This study tests whether adding targeted local treatment (like radiation to a few spots seen on scans) improves outcomes for some people with limited (oligometastatic) prostate cancer. It compares standard systemic therapy alone versus standard therapy plus PET-scan–guided spot treatment.
Long Beach, CaliforniaAges 18 years+ - NCT04734730RecruitingPhase 2
Talazoparib plus hormone therapy for metastatic prostate cancer
This trial tests whether talazoparib added to standard hormone therapy (ADT), along with abiraterone, can better control metastatic prostate cancer that hasn’t progressed despite starting hormone treatment. It may help people live longer and delay cancer worsening.
Duarte, CaliforniaAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Studying a new drug for cancers with a specific TP53 change
This trial tests a new drug (rezatapopt) for people with advanced cancers that have a specific change in the TP53 gene, called Y220C. The drug is designed to target this change and may slow or stop cancer growth. Some participants may also receive an immunotherapy drug called pembrolizumab (Keytruda).
Irvine, CaliforniaAges 12 years+ - NCT04423211RecruitingPhase 3
Surgery-recovered prostate cancer treated with PET-guided radiation
This trial tests whether adding targeted radiation guided by a PET scan (along with hormone therapy) can improve outcomes for prostate cancer that has come back after surgery. The PET scan helps doctors look for spots outside the usual radiation area so treatment can be tailored.
Anchorage, AlaskaAges 18 years+ - NCT04083937Recruiting
Radiation after prostate surgery for men with prostate cancer
This study looks at different radiation approaches after prostate surgery to see which strategy works best. You may be able to join if your cancer is at a stage where radiation to the prostate bed is planned, and you have not had prior radiation.
HeidelbergAges 18 years+ - NCT04104529Recruiting
Research database for metabolic radiotherapy patients
This study creates a database of information and blood samples from patients receiving a type of treatment called metabolic radiotherapy for certain cancers, like thyroid, neuroendocrine, or prostate cancer. It aims to improve understanding and care for future patients.
Bordeaux, AquitaineAges 18 years+ - NCT03821246RecruitingPhase 2
Atezolizumab and other drugs before prostate surgery for high-risk cancer
This Phase 2 trial tests whether giving immunotherapy (atezolizumab) plus another drug before surgery can shrink or control high-risk localized prostate cancer. The goal is to improve outcomes by treating the cancer early, before radical prostatectomy.
San Francisco, CaliforniaAges 18 years+ - NCT03237026Recruiting
Urine tests to predict outcomes in prostate cancer treatment
This study looks for urine markers (proteins and metabolites) that may help predict how prostate cancer patients respond to treatment and what their outcomes are. You may be asked to give a urine sample and allow use of your medical and treatment details for analysis (results are not shared with you).
TaipeiAges 30–100 - NCT03073278Recruiting
Targeted re-radiation for prostate cancer recurrence in one area
This study tests a focused radiation treatment (SBRT) to a small, clearly identified spot in the prostate for men whose prostate cancer has come back after prior external beam radiation. It may help control cancer while limiting radiation to the rest of the prostate and nearby organs.
St Leonards, New South WalesAges 18 years+ - NCT02997709Recruiting
Collecting prostate cancer body marker samples during treatment
This study collects and measures “biomarkers” (measurable signs in the body) from people with prostate cancer who are about to have surgery or radiation. The goal is to understand how prostate cancer behaves during treatment, which may help improve care in the future.
Miami, FloridaAges 30 years+ - NCT01834001Recruiting
MRI checks how prostate cancer responds to radiation
This study uses MRI scans to see how prostate cancer changes after radiation treatment, especially in the local (prostate-area) response. It may help doctors better judge treatment effectiveness and plan care more precisely.
Bethesda, MarylandAges 18–120 - NCT02016248Recruiting
Radiation “boost” for higher-risk prostate cancer
This trial studies whether adding a stronger “boost” dose of targeted radiation (SBRT) can better control higher-risk prostate cancer. It may help by increasing radiation coverage to the prostate while trying to limit treatment to surrounding areas.
Fountain Valley, CaliforniaAges 18 years+ - NCT07698535RecruitingPhase 2
Blood test to guide early stopping of prostate cancer therapy
This trial uses a blood test to measure tumor DNA and see if men with advanced prostate cancer can safely stop treatment with a drug called 177Lu-PSMA-617 earlier than usual, or switch to chemotherapy. It may help reduce side effects while still controlling the cancer.
Seattle, WashingtonAges 18 years+
Hear when a new Prostate Cancer Patients Treated by Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer patients treated by radiotherapy?
- Yes. Clin2 currently lists 269 recruiting prostate cancer patients treated by radiotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer patients treated by radiotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer patients treated by radiotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Prostate Cancer Patients
- Metastatic Castration-Resistant Prostate Cancer Patients
- Prostate Cancer Patients Undergoing Radical Prostatectomy
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Prostate Cancer
- Prostate Cancer (Adenocarcinoma)
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Stage IVB Prostate Cancer AJCC v8
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.